I think what was really interesting about the donanemab results was the response in those with intermediate levels of tau vs those with high levels of tau. It confirms the multifaceted nature of the disease and seems to support the view that AD treatment will evolve to have both a tau and amyloid targeted treatment arm and most likely a anti neuroinflammatory arm as well.
It would appear that there are going to be a very large number of combination trials that will need to be conducted in the AD space in the future.
Ann: Industry News, page-3
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
85.0¢ |
Change
-0.040(4.49%) |
Mkt cap ! $145.1M | |||
| Open | High | Low | Value | Volume |
| 87.0¢ | 88.0¢ | 79.5¢ | $884.9K | 1.083M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | 80.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 89.0¢ | 4016 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| CGS (ASX) Chart |